What is Lumos Diagnostics Holdings 1-Year ROIIC %?
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Lumos Diagnostics Holdings's 1-Year ROIIC % for the quarter that ended in Dec. 2024 was 314.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lumos Diagnostics Holdings's 1-Year ROIIC % or its related term are showing as below:
LDXHF's 1-Year ROIIC % is ranked better than 90.6% of 819
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs LDXHF: 314.66
Lumos Diagnostics Holdings 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lumos Diagnostics Holdings's 1-Year ROIIC %
For the Medical Devices subindustry, Lumos Diagnostics Holdings's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings's 1-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's 1-Year ROIIC % falls into.
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -4.96 (Dec. 2024) - -9.316 (Dec. 2023) )
/
( 22.907 (Dec. 2024) - 22.895 (Dec. 2023) )
=
4.356
/
0.012000000000004
=
36,300.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lumos Diagnostics Holdings 1-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LDXHF has been successfully added to your